Literature DB >> 1945607

Antibody responses to influenza B viruses in immunologically unprimed children.

R A Levandowski1, H L Regnery, E Staton, B G Burgess, M S Williams, J R Groothuis.   

Abstract

The cocirculation in several parts of the world of influenza viruses B/Yamagata/16/88 and B/Victoria/2/87, which are genetically and antigenically divergent, has prompted the question of whether immunization with one viral antigen is sufficient for protection against both strains. Twenty-three high-risk infants and young children were immunized with a commercial trivalent influenza vaccine containing the antigens of influenza virus B/Yamagata/16/88. When antibodies against influenza viruses B/Yamagata/16/88 and B/Victoria/2/87 were determined, increases developed uniformly to both in the sera of primed children previously exposed to influenza virus B/Victoria/2/87 by immunization or infection. Antibodies against B/Yamagata/16/88 developed in the sera of unprimed children with titers similar to those of the primed children. However, antibodies to B/Victoria/2/87 were not detected in the sera of the unprimed children. These data suggest that children without appropriate immunologic priming may not be protected against an infection with a B/Victoria/2/87 strain after vaccination with a B/Yamagata/16/88 strain. Immunization with more than one influenza B virus strain may be desirable in some high-risk pediatric patients if divergent influenza B viruses circulate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1945607

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  Transmission of influenza B viruses in the guinea pig.

Authors:  Natalie Pica; Yi-Ying Chou; Nicole M Bouvier; Peter Palese
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Increasing appearance of reassortant influenza B virus in Taiwan from 2002 to 2005.

Authors:  Huey-Pin Tsai; Hsuan-Chen Wang; David Kiang; Sheng-Wen Huang; Pin-Hwa Kuo; Ching-Chuan Liu; Ih-Jen Su; Jen-Ren Wang
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Statement on Seasonal Influenza Vaccine for 2011-2012: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-14

4.  Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-08-31

5.  STATEMENT ON SEASONAL INFLUENZA VACCINE FOR 2012-2013: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2012-08-01

6.  Statement on Seasonal Influenza Vaccine for 2013-2014: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2013-10-10

7.  Heterogeneity of influenza B virus strains in one epidemic season differentiated by monoclonal antibodies and nucleotide sequences.

Authors:  N Nakagawa; R Kubota; A Maeda; T Nakagawa; Y Okuno
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 8.  Humoral immune response to influenza vaccination in patients from high risk groups.

Authors:  L B Brydak; M Machala
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

9.  Diagnostic microarray for influenza B viruses.

Authors:  Daniela M Dankbar; Erica D Dawson; Martin Mehlmann; Chad L Moore; James A Smagala; Michael W Shaw; Nancy J Cox; Robert D Kuchta; Kathy L Rowlen
Journal:  Anal Chem       Date:  2007-03-01       Impact factor: 6.986

10.  Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases.

Authors:  Marcos C Vieira; Celeste M Donato; Philip Arevalo; Guus F Rimmelzwaan; Timothy Wood; Liza Lopez; Q Sue Huang; Vijaykrishna Dhanasekaran; Katia Koelle; Sarah Cobey
Journal:  Nat Commun       Date:  2021-07-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.